Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02715531
- Locations
- 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02711423
- Locations
- 🇺🇸
Bioclinica Research, Orlando, Florida, United States
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02708732
- Locations
- 🇬🇧
PH Associates - an OPen Health Company, Marlow, United Kingdom
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT02707640
Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02706067
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT02701985
- Locations
- 🇺🇸
Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, United States
🇺🇸Wallace Rheumatic Study Center, Beverly Hills, California, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 164
- Registration Number
- NCT02699372
- Locations
- 🇳🇱
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands
Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 130
- Registration Number
- NCT02699892
Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1009
- Registration Number
- NCT02699879
- Locations
- 🇦🇹
Medizinische Universitat Innsbruck; Department of Internal Medicine, Pneumology Centre, Innsbruck, Austria
🇩🇰Aarhus University Hospital; Lungemed afd. B, Aarhus, Denmark
🇦🇹LKH Hohenems; Abteilung für Pulmologie, Hohenems, Austria
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT02699450
- Locations
- 🇺🇸
United Med Res Inst, Inglewood, California, United States
🇺🇸Ophthalmic Clinical Trials San Diego, Oceanside, California, United States
🇺🇸Southern CA Desert Retina Cons, Palm Desert, California, United States